**Urgent Recall Issued for Paracetamol Batches Over Contamination Concerns**
Consumers across the UK have been urged to check their recent prescriptions after a major recall of paracetamol 500mg tablets was announced due to potential contamination. The Medicines and Healthcare products Regulatory Agency (MHRA) released a statement on Monday confirming that several batches manufactured by Chelonia Healthcare Limited are being withdrawn from circulation as a precautionary measure, after discolouration was observed in some tablets.
The announcement follows a small number of complaints from patients and pharmacists, who discovered tablets in some pots that appeared discoloured. While the exact cause of the contamination remains under investigation, health officials stress the importance of caution and swift action. The recall affects packs containing 100 tablets, which are only supplied on prescription in the UK.
According to the MHRA, affected tablets can be identified via batch numbers clearly printed on both the bottle label and the outer packaging. Patients currently holding a prescription for paracetamol 500mg tablets are encouraged to check these batch numbers promptly. If the medication is from any of the recalled batches, recipients are advised not to consume the tablets and should instead return them to the dispensing pharmacy.
The agency further clarified that the contaminated product is “paracetamol 500mg tablets”, packed in pots of 100. The batch numbers, along with other details such as the medicine’s active ingredient and relevant identification codes, have been circulated to healthcare professionals and are available for public reference. While these tablets are commonly used to manage fever and relieve mild to moderate pain, discoloured medication has the potential to pose health risks due to the unknown nature of the contamination.
In keeping with best safety practices, the MHRA instructed: “Patients or carers should verify whether their supplied tablets are from the listed batches. If any tablets are discoloured or otherwise appear altered, the medicine should not be used, and advice should be sought from a pharmacy or healthcare professional.” The patient information leaflet accompanying each container specifies that tablets should appear white, capsule-shaped, and scored on one side.
Those who have started taking the recalled tablets and experience any unusual side effects or possible adverse reactions are encouraged to seek medical advice immediately. The MHRA has also reminded the public to report any incidents or suspected side effects via its Yellow Card scheme, which serves as the UK’s system for gathering medicine safety information.
The recall has been designated as a Class 2 alert, meaning that while the defect could potentially lead to inappropriate treatment or harm, it is not expected to result in serious or life-threatening events. Nonetheless, the measure underscores a continued commitment by regulators to protect patient wellbeing and uphold strict pharmaceutical standards.
Pharmacists nationwide have received detailed guidance outlining the recall procedure. They have been instructed to halt supply of all affected batches immediately, quarantine any undistributed stock, and return it through the approved channels provided by suppliers. This coordinated response aims to remove all contaminated stock from circulation quickly, mitigating risk to the public.
At the time of reporting, there have been no confirmed cases of serious harm linked directly to the discoloured tablets. The recall has drawn attention to the importance of vigilance at every stage in the pharmaceutical supply chain, from manufacturing to dispensing, and highlights the need for patients to be proactive in checking their medicines. Anyone with questions or concerns regarding their prescription is strongly advised to reach out to their local pharmacist or GP for personalised guidance.